Cellectis (CLLS) Cash from Operations Growth (1y) (2016 - 2026)
Cellectis (CLLS) Cash from Operations Growth (1y) (2016 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Cellectis |
17.40 Bn |
17.21 Bn |
- |
10.20% |
| Date | Value |
|---|
| Mar 31, 2026 |
10.20% |
| Dec 31, 2025 |
-21,942.55% |
| Sep 30, 2025 |
73.05% |
| Jun 30, 2025 |
-119.76% |
| Mar 31, 2025 |
26.40% |
| Dec 31, 2024 |
-100.11% |
| Sep 30, 2024 |
65.90% |
| Jun 30, 2024 |
374.01% |
| Mar 31, 2024 |
17.69% |
| Dec 31, 2023 |
3,654.10% |
| Sep 30, 2023 |
34.36% |
| Jun 30, 2023 |
19.20% |
| Mar 31, 2023 |
22.63% |
| Dec 31, 2022 |
94.21% |
| Sep 30, 2022 |
14.41% |
| Jun 30, 2022 |
-94.38% |
| Mar 31, 2022 |
10.55% |
| Dec 31, 2021 |
37.79% |
| Sep 30, 2021 |
-18.81% |
| Jun 30, 2021 |
45.44% |
